2种头孢氨苄片在比格犬体内的药代动力学及生物等效性试验

doi:10.16431/j.cnki.1671-7236.2022.01.041

中国畜牧兽医 ›› 2022, Vol. 49 ›› Issue (1): 386-394.doi: 10.16431/j.cnki.1671-7236.2022.01.041

2种头孢氨苄片在比格犬体内的药代动力学及生物等效性试验

杨宇欣^1,2, 赵富华³, 刘羽^1,2, 邱基程^1,2, 曹玉颖^1,2, 张璐^1,2, 白如念⁴, 王建中⁵, 曹兴元^1,2

1. 中国农业大学动物医学院, 北京 100193;
2. 国家兽药残留基准实验室, 北京 100193;
3. 中国兽医药品监察所, 北京 100081;
4. 北京市动物疫病预防控制中心, 北京 100013;
5. 山西农业大学动物医学学院, 太谷 030801

收稿日期:2021-07-06 出版日期:2022-01-05 发布日期:2021-12-29
通讯作者: 王建中, 曹兴元 E-mail:wjz2020@foxmail.com;cxy@cau.edu.cn
作者简介:杨宇欣,E-mail:1335168895@qq.com。
基金资助:
抗菌药物代谢转归及环境微生态风险评估（2018YFD0500301）

Pharmacokinetics and Bioequivalence of Two Cephalexin Formulations in Beagle Dogs

YANG Yuxin^1,2, ZHAO Fuhua³, LIU Yu^1,2, QIU Jicheng^1,2, CAO Yuying^1,2, ZHANG Lu^1,2, BAI Runian⁴, WANG Jianzhong⁵, CAO Xingyuan^1,2

1. College of Veterinary Medicine, China Agricultural University, Beijing 100193, China;
2. Reference Laboratory for the Test of Veterinary Drug Residues, Beijing 100193, China;
3. China Institute of Veterinary Drug Control, Beijing 100081, China;
4. Beijing Center for Animal Diseases Prevention and Control, Beijing 100013, China;
5. College of Veterinary Medicine, Shanxi Agricultural University, Taigu 030801, China

Received:2021-07-06 Online:2022-01-05 Published:2021-12-29

摘要/Abstract

摘要： [目的] 研究头孢氨苄片受试制剂和参比制剂在比格犬体内的生物等效性。[方法] 采用双周期和双序列交叉设计，将22只健康比格犬随机分成2组，按30 mg/kg BW分别单剂量口服头孢氨苄片受试制剂Trolevis^®300和参比制剂Rilexine^®300，于给药前（0 h）和给药后0.5、1、1.5、2、2.5、3、4、6、8、12、17和24 h从臂头静脉采血。对超高效液相色谱串联质谱（UPLC-MS/MS）方法进行特异性、线性、检测限、准确度、精密度、稳定性等方法学考察。利用建立好的UPLC-MS/MS方法测定血浆中的药物浓度，并用WinNonlin^TM 8.1软件对药代动力学参数进行分析计算。[结果] 方法学结果显示，在100~5 000 ng/mL浓度范围内相关性良好，相关系数（R²）≥ 0.99，标准曲线方程为y=10.6828x-176.481；高、中、低3个浓度的相对回收率平均值分别为105.63%、104.35%和102.40%；日内和日间变异系数均<15%；检测限为50 ng/mL，定量限为100 ng/mL。药代动力学结果显示，参比制剂组和受试制剂组药代动力学参数如下：T_max分别为（1.77±0.55）和（2.70±4.68）h；C_max分别为（28.09±5.09）和（26.82±7.94）μg/mL；T_1/2分别为（3.39±1.43）和（3.12±1.05）h；AUC_0-t分别为（121.81±25.80）和（116.34±36.30）μg·h/mL。受试制剂与参比制剂药时曲线相似，且受试制剂与参比制剂C_max、AUC_0-t和AUC_0-∞几何均数的比值分别为99.51%、99.27%和99.30%，其90% CI均在80.00%~125.00%之间。[结论] 本试验建立的UPLC-MS/MS方法准确、可靠，可用于头孢氨苄的浓度测定，且头孢氨苄受试制剂与参比制剂是等效的，临床上均可用于相关疾病的治疗。

关键词: 药代动力学; 生物等效性; 比格犬; 头孢氨苄片; 超高效液相色谱串联质谱

Abstract: [Objective] The purpose of the experiment was to study the bioequivalence of cephalexin test and reference formulations in Beagle dogs. [Method] Twenty-two Beagle dogs were randomly allocated to two equal-sized treatment groups in a randomized dual-cycle and dual-sequence cross-over design. The test (Trolevis^®300) and the reference (Rilexine^®300) formulations were orally administered in a single dose of 30 mg/kg BW. Blood samples were collected from brachiocephalic vein at 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 17 and 24 h after administration. The specificity, linearity, detection limit, accuracy, precision, and stability of UPLC-MS/MS method were investigated. The concentration of cephalexin in plasma was determined by UPLC-MS/MS. The pharmacokinetic parameters were analyzed and calculated with WinNonlin^TM 8.1. [Result] The methodological results showed good correlation over the concentration range of 100-5 000 ng/mL with a correlation coefficient (R²) ≥ 0.99 and a standard curve equation of y=10.6828x-176.481. Relative recoveries were 105.63%, 104.35% and 102.40% for high, medium and low concentrations. Coefficient variations of intra-day and inter-day were all less than 15%, and the limit of detection and the limit of quantification were 50 and 100 ng/mL, respectively. The pharmacokinetic parameters of the two groups were as follows:T_max were (1.77±0.55) and (2.70+4.68) h, C_max were (28.09±5.09) and (26.82±7.94) μg/mL;T_1/2 were (3.39±1.43) and (3.12±1.05) h;AUC_0-t were (121.81±25.80) and (116.34±36.30) μg·h/mL. The plasma profiles of cephalexin following the administration of both formulations were similar. And the ratio of the average C_max, AUC_0-t and AUC_0-∞ of the test/reference preparation were 99.51%, 99.27% and 99.30% respectively, the 90% CI all fell between 80.00%-125.00%. [Conclusion] The UPLC-MS/MS method established in this experiment was accurate and reliable, and could be used to determine the concentration of cephalexin. The two formulations were bioequivalent for cephalexin, and could be used clinically for the treatment of related diseases.

Key words: pharmacokinetics; bioequivalence; Beagle dog; cephalexin tablets; UPLC-MS/MS

中图分类号:

S89.79⁺6

杨宇欣, 赵富华, 刘羽, 邱基程, 曹玉颖, 张璐, 白如念, 王建中, 曹兴元. 2种头孢氨苄片在比格犬体内的药代动力学及生物等效性试验[J]. 中国畜牧兽医, 2022, 49(1): 386-394.

YANG Yuxin, ZHAO Fuhua, LIU Yu, QIU Jicheng, CAO Yuying, ZHANG Lu, BAI Runian, WANG Jianzhong, CAO Xingyuan. Pharmacokinetics and Bioequivalence of Two Cephalexin Formulations in Beagle Dogs[J]. China Animal Husbandry and Veterinary Medicine, 2022, 49(1): 386-394.

参考文献

[1] VOBECKA L,TICHA L,ATANASOVA A,et al.Enzyme synthesis of cephalexin in continuous-flow microfluidic device in ATPS environment[J].Chemical Engineering Journal,2020,396:125236.
[2] NAZARI G,ABOLGHASEMI H,ESMAIELI M.Batch adsorption of cephalexin antibiotic from aqueous solution by walnut shell-based activated carbon[J].Journal of the Taiwan Institute of Chemical Engineers,2016,58(1):357-365.
[3] HAO A Y,WANG X Q,MEI Y Z,et al.A smartphone-combined ratiometric fluorescence probe for specifically and visibly detecting cephalexin[J].Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy,2020,249:119310.
[4] 李梅,孙灵灵,袁宗辉,等.兽用头孢菌素类抗生素研究进展[J].中国畜牧兽医,2018,45(7):1978-1989. LI M,SUN L L,YUAN Z H,et al.Research progress on veterinary cephalosporins[J].China Animal Husbandry & Veterinary Medicine,2018,45(7):1978-1989.(in Chinese)
[5] 王志强.犬猫——临床用药用册(精)[M].上海:上海科技出版社,2009. WANG Z Q.Dogs and Cats-Clinical Medication Book (Essence)[M].Shanghai:Shanghai Science and Technology Press,2009.(in Chinese)
[6] JAWAD A M,ALJAMALIL N M,JAWAD A M,et al.Innovation,preparation of cephalexin drug derivatives and studying of (toxicity & resistance of infection)[J].International Journal of Psychosocial Rehabilitation,2020,24(4):3754.
[7] 吴健鸿,杨远荣,崔晶,等.国产头孢氨苄片与国外同品种的人体生物等效性研究[J].医药导报,2007,26(5):480-480. WU J H,YANG Y R,CUI J,et al.Bioequivalence evaluation of domestic cefalexin tablets compared with the same US product in Chinese healthy volunteers[J].Herald of Medicine,2007,26(5):480-480.(in Chinese)
[8] 祁静波,王敏,谢鹏,等.头孢氨苄胃漂浮缓释片的制备与质量评价[J].西北药学杂志,2020,35(1):98-102. QI J B,WANG M,XIE P,et al.Preparation and quality evaluation of cephalexin gastric floating sustained-release tablets[J].Northwest Pharmaceutical Journal,2020,35(1):98-102.(in Chinese)
[9] FRANK L A,KUNKLE G A.Comparison of the efficacy of cefadroxil and generic and proprietary cephalexin in the treatment of pyoderma in dogs[J].Journal of the American Veterinary Medical Association,1993,203(4):530-533.
[10] TOMA S,COLOMBO S,CORNEGLIANI L,et al.Efficacy and tolerability of once-daily cephalexin in canine superficial pyoderma:An open controlled study[J].Journal of Small Animal Practice,2008,49(8):384-391.
[11] SHAHBAZ K.Cephalosporins:Pharmacology and chemistry[J].Pharmaceutical and Biological Evaluations,2017,4(6):234-238.
[12] BATAINEH Y A,AL A,AGA K,et al.Bioequivalence and pharmacokinetic evaluation of two batches of cephalexin capsules in healthy volunteers[J].Journal of Pharmaceutical Sciences and Research,2020,12(1):119-123.
[13] YIN L F,QIN C,CHEN K S,et al.Gastro-floating tablets of cephalexin:Preparation and in vitro/in vivo evaluation[J].China Pharmaceutical Conference,2013,452(1-2):241-248.
[14] PRADOS A P,AMBROS L,MONTOYA L,et al.Chronopharmacological study of cephalexin in dogs[J].Chronobiology International,2007,24(1):161-170.
[15] EVERTS R J,GARDINER S J,ZHANG M,et al.Probenecid effects on cephalexin pharmacokinetics and pharmacodynamics in healthy volunteers[J].Journal of Infection,2021,83(2):182-189.
[16] PAPICH M G,DAVIS J L,FLOERCHINGER A M.Pharmacokinetics,protein binding,and tissue distribution of orally administered cefpodoxime proxetil and cephalexin in dogs[J].American Journal of Veterinary Research,2010,71(12):1484-1491.
[17] ALBARELLOS G A,MONTOVA L,QUAINE P C,et al.Pharmacokinetics and bioavailability of a long-acting formulation of cephalexin after intramuscular administration to cats[J].Research in Veterinary Science,2011,91(1):129-131.
[18] HU L Q,YIN C L,DU Y H,et al.Simultaneous and direct determination of vancomycin and cephalexin in human plasma by using HPLC-DAD coupled with second-order calibration algorithms[J].Journal of Analytical Methods in Chemistry,2012,2012:256963.
[19] DO NASCIMENTO T G,DE JESUS OLIVEIRA E,BASÍLIO JÚNIOR I D,et al.Short-term stability studies of ampicillin and cephalexin in aqueous solution and human plasma:Application of least squares method in Arrhenius equation[J].Journal of Pharmaceutical & Biomedical Analysis,2013,73:59-64.
[20] HUSSEIN R F,HAMMAMI M M.Determination of cephalexin level and stability in human plasma by fully validated rapid HPLC analysis[J].World Journal of Pharmacy and Pharmaceutical Sciences,2014,3(12):20-31.
[21] FDA.Draft guidance for industry on bioanalytical method validation[EB/OL].[2020-03-23].https://www.regulations.gov/document/FDA-2013-D-1020-0002.
[22] QI M L,WANG P,SUN P,et al.Liquid chromatographic method for the simultaneous determination of cefalexin and trimethoprim in dog plasma and application to the pharmacokinetic studies of a coformulated preparation[J].Journal of Chromatography B,2006,832(2):307-312.
[23] PRADOS A P,KREIL V,ALBARELLOS G,et al.Metoclopramide modifies oral cephalexin pharmacokinetics in dogs[J].Journal of Veterinary Pharmacology & Therapeutics,2010,30(2):127-131.
[24] 国家药品监督管理局药品审评中心.化学药物制剂人体生物利用度和生物等效性研究技术指导原则[EB/OL].[2020-03-23].http://www.cde.org.cn/news.do?method=largeInfo&id=df886b70ab776419. CDE.Technical guidelines for research on human bioavailability and bioequivalence of chemical pharmaceutical preparations China[EB/OL].[2020-03-23].http://www.cde.org.cn/news.do?method=largeInfo&id=df886b70ab776419. (in Chinese)

2种头孢氨苄片在比格犬体内的药代动力学及生物等效性试验

Pharmacokinetics and Bioequivalence of Two Cephalexin Formulations in Beagle Dogs

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王志华, 贾俊鹏, RADEBE Stoffel Matjeke, 庾庆华. 微生态制剂调控比格幼犬生长性能和肠道菌群的研究[J]. 中国畜牧兽医, 2022, 49(2): 510-520.
[2]	蒲善菊, 黄玲利, 米坤, 孙达, 王涵宇, 潘源虎, 刘振利. 盐酸头孢噻呋注射液在猪体内的比较药动学研究[J]. 中国畜牧兽医, 2021, 48(4): 1472-1481.
[3]	张乐, 张广峰, 朱崇淼, 吴植, 朱善元, 于生兰, 封琦, 邢晓玲, 赵倩楠. 环糊精包合氟苯尼考在猪体内的药代动力学研究[J]. 中国畜牧兽医, 2020, 47(6): 1934-1941.
[4]	刘营营, 岳治光, 吴宁鹏, 刘珍珍, 闫亚群, 张素梅, 菅复春, 张龙现, 王荣军, 宁长申. 伊维菌素长效透皮剂和普通注射剂在家兔体内的药代动力学比较研究[J]. 中国畜牧兽医, 2020, 47(1): 267-274.
[5]	韩一晴, 纪迅, 陈春琴, 刘明江, 李金贵. 液相色谱-质谱联用法研究青蒿素在鸡体内的代谢规律[J]. 中国畜牧兽医, 2019, 46(9): 2778-2786.
[6]	时菲菲, 王婧, 秦枫, 陈晓兰, 高建如, 魏宇, 张龙. 新型兽用纳米乳载药系统在大鼠体内的药代动力学研究[J]. 《中国畜牧兽医》, 2019, 46(4): 1236-1243.
[7]	蒋志惠, 张静苗, 曲毅程, 张守泉, 常雪梅, 郭晓. 汤阴北艾精油对鼠CYP450酶活性和表达的影响[J]. 中国畜牧兽医, 2019, 46(11): 3440-3448.
[8]	李娇, 李庆山, 徐凤波. 莫西菌素在畜牧业中的应用研究进展[J]. 《中国畜牧兽医》, 2018, 45(12): 3587-3593.
[9]	郝宝成, 权晓弟, 叶永丽, 高旭东, 黄鑫, 王学红, 刘建枝, 王保海, 梁剑平. 疯草解毒复方中药制剂的药代动力学研究[J]. , 2016, 43(6): 1550-1556.
[10]	权晓弟，郝宝成，王学红，刘建枝，王保海，卢超，薛慧文，梁剑平. 速康解毒口服液在试验大鼠体内药代动力学研究[J]. 中国畜牧兽医, 2014, 41(2): 129-135.
[11]	金之源, 周泽伟, 王雅琴, 卜仕金. 猫经口内服2种米尔贝肟吡喹酮片的药代动力学比较研究[J]. , 2014, 41(12): 157-160.
[12]	王瑛莹;方炳虎;范炜达;王林. 喹烯酮及其主要代谢物在猪体内的药动学研究[J]. , 2012, 39(5): 213-216.
[13]	赵蕾蕾;杨娟;刘义明;李鹏飞;王中杰;苏丹;李秀波. 动物专用抗原虫药咪唑苯脲研究进展[J]. , 2012, 39(2): 151-155.
[14]	战大伟, 牛春, 颜克松, 李洁, 徐晨, 刘金毅. 重组人干扰素α1b喷雾剂皮肤局部药代动力学研究[J]. , 2012, 39(10): 163-165.
[15]	张瑞丽;崔亮亮;郝智慧;赵永达. 5种伊维菌素注射液在家兔体内的比较药动学研究[J]. , 2011, 38(11): 188-190.